BrightPath Biotherapeutics
BrightPath Biotherapeutics is dedicated to pioneering immunotherapy to enable a world where cancer patients can defeat cancer on their own. The company focuses on developing innovative cancer immunotherapeutic agents, including cell therapy, antibody drugs, and cancer vaccines, with a mission to be the 'light of hope' in cancer treatment and to illuminate the field of cancer immunotherapy with science.
Industries
Nr. of Employees
small (1-50)
BrightPath Biotherapeutics
Kojimachi Central Building 7F, 2-2-4 Kojimachi, Chiyoda-ku, Tokyo 102-0083
Products
iPSC-derived NKT cell therapy (allogeneic)
Allogeneic NKT cell therapy produced by differentiating NKT cells from iPSC master cell banks for use in oncology indications.
HER2-targeted CAR-T cell therapy
CAR-T cell therapy program targeting the HER2 tumor antigen for oncology indications.
BCMA-targeted CAR-iNKT cell therapy
iPSC-derived NKT cell platform engineered with a CAR targeting BCMA for hematologic malignancies.
Bispecific antibody for cancer therapy
Bispecific antibody program developed for oncology applications (preclinical/early clinical data presented at scientific meetings).
Cancer peptide and neoantigen vaccine programs
Peptide-based and personalized neoantigen vaccine development programs for oncology immunotherapy.
CD73 antagonist antibody
Preclinical antibody program targeting CD73 as an immune-modulating strategy in oncology.
iPSC-derived NKT cell therapy (allogeneic)
Allogeneic NKT cell therapy produced by differentiating NKT cells from iPSC master cell banks for use in oncology indications.
HER2-targeted CAR-T cell therapy
CAR-T cell therapy program targeting the HER2 tumor antigen for oncology indications.
BCMA-targeted CAR-iNKT cell therapy
iPSC-derived NKT cell platform engineered with a CAR targeting BCMA for hematologic malignancies.
Bispecific antibody for cancer therapy
Bispecific antibody program developed for oncology applications (preclinical/early clinical data presented at scientific meetings).
Cancer peptide and neoantigen vaccine programs
Peptide-based and personalized neoantigen vaccine development programs for oncology immunotherapy.
CD73 antagonist antibody
Preclinical antibody program targeting CD73 as an immune-modulating strategy in oncology.
Services
Design and conduct of oncology clinical trials across early and late phases, including company-sponsored and investigator-initiated studies.
Process development and scale-up for iPSC-derived cell therapy products, including master cell bank-based production and manufacturing data presentations.
Establishing joint research agreements, collaborative development programs, and licensing arrangements with academic and industry partners.
Design and conduct of oncology clinical trials across early and late phases, including company-sponsored and investigator-initiated studies.
Process development and scale-up for iPSC-derived cell therapy products, including master cell bank-based production and manufacturing data presentations.
Establishing joint research agreements, collaborative development programs, and licensing arrangements with academic and industry partners.
Expertise Areas
- Allogeneic iPSC-derived cell therapy development
- CAR-T and CAR-iNKT engineering
- Cancer immunotherapy (antibodies and cell therapy)
- Neoantigen and peptide vaccine development
Key Technologies
- Induced pluripotent stem cell (iPSC) differentiation
- Allogeneic cell therapy manufacturing
- Chimeric antigen receptor (CAR) engineering
- Bispecific antibody formats
News & Updates
Financial results report for Q2 FY2025, Japanese GAAP, non-consolidated.
BP2202 received orphan drug designation from the U.S. FDA for the treatment of multiple myeloma.
Data presentation on BP1212 for cancer therapy at IRCI 2025.
Financial results report for Q2 FY2025, Japanese GAAP, non-consolidated.
BP2202 received orphan drug designation from the U.S. FDA for the treatment of multiple myeloma.
Data presentation on BP1212 for cancer therapy at IRCI 2025.